Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Steffan

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Agents and Actions|January 1, 1993
Structure-activity relationships leading to WAY-121,520, a tris aryl-type, indomethacin-based, phospholipase A2 (PLA2)/leukotriene biosynthesis inhibitorA Kreft, J Nelson, J Musser, et al.
Drugs Under Experimental and Clinical Research|January 1, 1991
Conversion of a cyclooxygenase (CO) inhibitor into a 5-lipoxygenase (LO) inhibitor: a general route to novel orally active anti-inflammatory and anti-allergy drugsA F Kreft, A A Failli, J H Musser, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Agents and Actions|January 1, 1993
Structure-activity relationships leading to WAY-121,520, a tris aryl-type, indomethacin-based, phospholipase A2 (PLA2)/leukotriene biosynthesis inhibitorA Kreft, J Nelson, J Musser, et al.
Drugs Under Experimental and Clinical Research|January 1, 1991
Conversion of a cyclooxygenase (CO) inhibitor into a 5-lipoxygenase (LO) inhibitor: a general route to novel orally active anti-inflammatory and anti-allergy drugsA F Kreft, A A Failli, J H Musser, et al.
Pageof 2